SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer

Table 5

Multivariable analysis of prognostic parameters for survival in gastric cancer patients.

Variable	Multivariable analysis
	HR (95% CI)	value^d
SFRP4 (high vs. low)	2.174 (1.196–3.951)	0.011
Family history (yes vs. no)	2.318 (1.217–4.414)	0.011
Tumor location (proximal gastric cancer vs. total stomach)	0.542 (0.208–1.413)	0.210
Tumor location (distal gastric cancer vs. total stomach)	0.412 (0.154–1.103)	0.078
Borrmann type (I/II vs. III/IV)	0.694 (0.423–1.136)	0.146
Lauren type (intestinal vs. mixed)	0.701 (0.341–1.440)	0.333
M stage (M0 vs. M1)	0.501 (0.249–1.008)	0.053
TNM stage (I/II/III vs. IV)	0.501 (0.249–1.008)	0.053
Vascular invasion (positive vs. negative)	1.549 (0.897–2.674)	0.116
CD4 (high vs. low)	0.896 (0.504–1.593)	0.708
CD8 (high vs. low)	0.594 (0.345–1.022)	0.060

^dStatistically significant ().